Latest Tax Refunds News

Evolution Energy Minerals initiates a strategic review and cost-cutting at its Chilalo graphite project while progressing a farm-out deal for its Chikundu Cu-Pb-Zn VHMS prospect with Oscillate plc.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Red Metal Limited's March 2025 quarterly report reveals robust progress across its rare earth and base metals projects, underpinned by promising drilling results and supportive government funding.

Barton Gold Holdings reported a 120,000-ounce gold resource increase at Tunkillia and uncovered exceptional high-grade silver at Tarcoola’s Tolmer prospect, alongside a $3.1 million half-year profit and accelerated feasibility studies.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

VHM Limited has achieved a key milestone with mining licence approval for its Goschen Rare Earths and Mineral Sands Project, alongside a revised staged expansion plan that adjusts capital and operating costs while extending Major Project Status.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Andromeda Metals has entered exclusive negotiations for a $75 million debt facility to fund the Stage 1A+ development of its Great White Project, alongside operational progress and exploration drilling.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Critica Limited has declared a maiden Inferred Mineral Resource Estimate for its Jupiter Project, establishing it as Australia’s largest and highest-grade clay-hosted rare earth deposit. Early metallurgical testwork shows promising beneficiation results, positioning the company as a strategic player in the rare earths sector.